Terry C. Lairmore, MD, FACS
Professor, Department of Surgery
Donnie and Gail Juneau Endowed Chair in Surgical Oncology
Chief of Division of Endocrine and Oncologic Surgery
Learn more: https://pubmed.ncbi.nlm.nih.gov/?term=lairmore+tc
- Research
- Grants & Funding
- Publications
- Clinical Trials
- Appointments
- Education
- Honors & Awards
- Contact
Research
Dr. Lairmore and his research team study the rare and aggressive cancer cholangiocarcinoma (CCA), which arises from the bile duct epithelium. There are no effective treatments for CCA, and little is known about the biology of the disease.
Dr. Lairmore and his team recently analyzed approximately 100 patient CCA tumors and found that that there is a significant decrease in the expression of the menin tumor suppressor protein in high grade CCAs. The overarching hypothesis is that the loss of menin in high grade CCA upregulates a disease-defining molecular pathway that promotes an aggressive phenotype and progression. Using patient tumors and a variety of techniques, including RNAseq and a synthetic genetic screen, Dr. Lairmore and his team will test this hypothesis. This work could lead to novel targets for therapeutics.
The collaborative research group also focuses on the role of menin in liver fibrotic states, and disparities in treatment and disease outcomes for cholangiocarcinoma. Future projects will focus on epigenetic effects of age on thyroid cancer outcomes.
The collaborative research group is interdepartmental and includes Dr. Stephan Witt, Dr. Arrigo De Benedetti, and Dr. Shile Huang in the Department of Biochemistry and Molecular Biology at LSU Health Shreveport, as well as Dr. Jehan Abdulsattar in the Department of Pathology.
Grants & Funding
PRESENT FUNDING
Funding Agency: Feist-Weiller Intramural Award (S.Thayer)
Period: 9/1/21 through 6/30/22
Grant Title: Role of Menin in Cholangiocarcinoma
Principal Investigator: Terry C. Lairmore, MD
Co-Investigators: Stephen Witt, PhD; Arrigo De Benedetti, PhD; Shile Huang, PhD; Jehan Abdulsattar, MD
Total Award: $20,000
RECENT PAST FUNDING
- Funding Agency: LBRN and LA CaTS Translational Science Project (https://lbrn.lsu.edu/)
Period: 5/1/2022-4/30/2022
Grant Title: Disparities in Breast Cancer Treatment Outcomes: Improving Access with Health Informatics
Principal Investigator: Urska Cvek, PhD
Co-Investigators (Mentors): Terry C. Lairmore, MD, Jane Sugar, MD
Total Award: $54,007 ($40,000 direct) - Funding Agency: Research Mentorship Award – Scott & White
Period: 4/15-4/17
Grant Title: The Role of Menin in the Regulation of Cholangiocyte Growth
Principal Investigator: Terry C. Lairmore, MD
Co-Investigators: Laurent Ehrlich, MS, Shannon Glaser, PhD, Gianfranco Alpini, PhD
Total Award: $10,000 - Funding Agency: Department of Surgery Wigley Research Award, Scott & White
Period: 12/08-11/09
Grant Title: Mutations in the Epidermal Growth Factor Receptor (EGFR) Gene in Bronchioloalveolar Lung Cancer
Principal Investigator: Terry C. Lairmore, MD
Total Costs: $25,000
Publications
List of Recent Publications
-
Albert P, Aziz M, Connelly Z, Lairmore T, Virk C. Comparison of Bovine Artery and Polytetrafluoroethylene (PTFE) Grafts for Hemodialysis Access, Submitted, Annals of Vascular Surgery, December 2022.
-
Kilgore, PCSR, Lairmore TC, Clifford EP, Sugar JG, Maniscalco LS, Li T, Trutschl M, Cvek U. Impact of Travel Distance to Treatment Facility on Outcomes for Louisiana Breast Cancer Patients. Submitted, December 2022.
-
Lairmore TC, Abdulsattar J, De Benedetti A, Shi R, Huang S, Khalil I, Witt SN. Loss of Tumor Suppressor Menin Expression in High Grade Cholangiocarcinomas. BMC Research Notes, Under Review, December 2022.
-
Morisetti M, Cotelingam J, Welch VL, Lairmore, TC. Incidental Richter’s transformation in mesenteric lymph node. Submitted, Journal of Case Reports, September 2022.
-
Lairmore TC, Chi D, Howe JR. From bedside to bench in multiple endocrine neoplasia Type 2: Samuel A. Wells, Jr. The Surgeon-Scientist. Submitted, Current Problems in Surgery, March 2022.
-
Albert P, Arrieta J, Lairmore T, Rao V, White K, Sugar M, Aziz M, Virk C. A retrospective review of bovine artery graft patency: A single site study. Submitted, International Journal of Surgery, April 2021.
- Shackelford RE, Ozluk E, Feng X, Abdulsatter J, Lairmore TC, Chu Q, Siriwardane NC, Cotelingam J. Pure large cell neuroendocrine carcinoma of the gallbladder: Case report of a rare entity. In press, Case Reports in Oncology, April 2021.
- Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49:1-33, 2020. doi 10.1097/MPA.0000000000001454. PMID: 31856076
- Campbell RA, Young DS, Shaver CN, Snyder SK, Milan SA, Lairmore TC, McDonald DK. Influence of adrenal venous sampling on management in patients with primary aldosteronism independent of lateralization on cross-sectional imaging. Journal of the American College of Surgeons 229(1):116-124, 2019. doi:10.1016/j.jamcollsurg.2019.03.012. Epub 2019 Mar 28. PMID: 30930101
- Hall CM, LaSeur DC, Snyder SK, Lairmore TC. Reoperative central lymph node dissection for incidental papillary thyroid cancer can be performed safely: A retrospective review. International Journal of Surgery 56:102-107, 2018. doi:10.1016/j.ijsu.2018.06.015. Epub 2018 Jun 18. PMID: 29920338
- Hall CM, Snyder SK, Lairmore TC. Central lymph node dissection improves lymph node clearance in papillary thyroid cancer patients with lateral neck metastases, even after prior total thyroidectomy. The American Surg. 2018 Apr 1;84(4):531-536. PMID: 29712601
- Ehrlich L, Scrushy M, Meng F, Lairmore TC, Alpini G, Glaser S. Biliary epithelium: A neuroendocrine compartment in cholestatic liver disease. Clinics and Research in Hepatology and Gastroenterology. 2018 Sep;42(4):296-305. doi: 10.1016/j.clinre.2018.03.009. Epub Apr 17 2018 Apr 17. PMID: 29678444
- Ehrlich L, O'Brien A, Hall C, White T, Chen L, Wu N, Venter J, Scrushy M, Mubarak M, Meng F, Dostal D, Wu C, Lairmore TC, Alpini G, Glaser S. α7-nAChR Knockout Mice Decreases Biliary Hyperplasia and Liver Fibrosis in Cholestatic Bile Duct-Ligated Mice. Gene Expression. 18(3):197-207, 2018. doi:10.3727/105221618X15216453076707. Epub Mar 26 2018. PMID: 29580318
- Hall C, Ehrlich L, Meng F, Invernizzi P, Bernuzzi F, Lairmore TC, Alpini G, Glaser S. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2-/- mice. Journal of Surgical Research, 217:160-169, 2017. doi: 10.1016/j.jss.2017.05.020. [Epub ahead of print]. PMID: 28602220
- Ehrlich L, Hall C, Meng F, Lairmore T, Alpini G, Glaser S. A review of the scaffold protein menin and its role in hepatobiliary pathology. Gene Expression 17(3):251-263, 2017. doi:10.3727/105221617X695744. [Epub 2017 Apr 28], PMID: 28485270
Clinical Trials
Listing of Clinical Trials
- An open label, stratified, single arm phase II study of RAD001 (everolimus), in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy. #060688 Closed to patient accrual
Novartis
Site: Scott & White Hospital, Temple Texas
Principal Investigator: Terry C. Lairmore, MD
Co-investigators: Arthur E. Frankel, MD
Primary objective: To determine the objective response rate (including complete response and partial response) or RAD001 10 mg po qd monotherapy in patients with advanced (unresectable or metastatic) pancreatic NETs after the failure of cytotoxic chemotherapy. - A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo. #060828 Closed to patient accrual
Novartis
Site: Scott & White Hospital, Temple Texas
Principal Investigator: Terry C. Lairmore, MD
Co-investigators: Arthur E. Frankel, MD, Lucas Wong, MD
Primary objective: To determine whether treatment with RAD001 10 mg/d plus Sandostatin LAR prolongs the progression free survival (PFS) compared to treatment with Sandostatin LAR alone in patients with advanced carcinoid tumor. - Randomized trial of surgical treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1 (MEN 1). Completed, 2014.
Site: Scott & White Hospital, Temple Texas
Principal Investigator: Terry C. Lairmore, MD
Primary objective: This study is the first randomized prospective trail comparing the outcomes of subtotal parathyroidectomy versus total parathyroidectomy and heterotopic autotransplantation in patients with the familial multiple endocrine neoplasia type 1 (MEN 1) syndrome. Presented at the American Association of Endocrine Surgeons meeting, Boston, Massachusetts, April 2014
Appointments
List of Current and Previous Appointments
Medical Quality Review Committee (MQRC), Ochsner LSU Health, 1/2020 to present
Chairman, Surgical Quality Council, LSU Health Shreveport 5/2020 to present
Surgery Quality Council, LSU Health Shreveport, 7/2019 to 4/2020
Program Evaluation Committee, LSU Health Shreveport, 7/2019 to present
Director, Division of Surgical Oncology, Scott & White, 2005-2018
Promotion and Tenure Committee, Department of Surgery, 2015
Associate Director for Research, Scott & White Cancer Institute, 2013
Chairman, Tenure and Faculty Promotions Committee, College of Medicine, Texas A&M University System Health Sciences Center, 2011-2012
Tenure and Faculty Promotions Committee, College of Medicine, Texas A&M University System Health Sciences Center, Sept. 2006-2012
Chairman, Tissue Bank Committee, Scott & White Hospital 2009-2015
Scott & White Research Grants Program Committee 2006
Chairman, Department of Surgery Research Committee, Scott & White Hospital 2006-2008
15th Annual Anesthesia Clinical Update and Resident Research Forum (Invited Referee), Scott & White, Temple, Texas 2006
Research Oversight Committee, Department of Anesthesia, Scott & White, Temple, Texas 2006
Advisory Committee, American Cancer Society-Institutional Research Grants, Washington University, St. Louis, Missouri
Advisory Committee, General Clinical Research Center (GCRC), Washington University School of Medicine, St. Louis, Missouri
Chairman, Surgical Case Review Committee, John Cochran Veteran's Administration Hospital, St. Louis, Missouri, 1997-2005
Associate Chief of Surgery; Program Director, Unit I Surgery, John Cochran Veteran's Administration Hospital, St. Louis, Missouri, 2005
Education
Education & Training
Undergraduate: Baylor University, Waco, Texas, Bachelor of Science in Biology, 1984
Graduate: Vanderbilt University School of Medicine, Doctor of Medicine, 1988
Postgraduate: Intern Barnes Hospital /Washington University School of Medicine, Department of General Surgery, 1988-1989
Research Fellow: Washington University School of Medicine, Departments of Surgery and Genetics, 1989-1992
Resident: Barnes Hospital /Washington University School of Medicine and Chief Resident Department of General Surgery, 1992 - June 30, 1995
Senior Registrar: Royal Infirmary, Edinburgh, Scotland, April 1994-October 1994
Honors & Awards
List of Honors & Awards
Gold Humanism Honor Society, (election by medical students and current GHHS members), LSU Health Shreveport, March 5, 2022
Texas Surgical Society, James E. Thompson Award for Best Paper by a New Member, April 2009
Valedictorian and Founder's Medal, Vanderbilt University School of Medicine, 1988
Upjohn Award, Vanderbilt University School of Medicine, 1988
Vanderbilt Third Year Surgery Clerkship Award, 1987
Alpha Omega Alpha Honor Medical Society, 1986
Phi Beta Kappa, Baylor University, 1984
Summa Cum Laude (GPA 4.0), Baylor University, 1984
Henry L. Robinson Phi Beta Kappa Scholarship, Baylor University, 1983-1984
Contact
LSU Health Shreveport
Department of Surgery
1501 Kings Highway
Shreveport, LA 71103
Email: Terry.Lairmore@lsuhs.edu
